Nautilus Biotechnology, Inc.
10.10%
12,815,113
1808805
63909J108
Jun 19, 2025
Jun 24, 2025, 04:42 PM
Reporting Persons (3)
This is a joint filing. The reported shares may overlap between reporting persons and should not be summed.
| Name | Type | % of Class | Aggregate | Sole Voting | Shared Voting |
|---|---|---|---|---|---|
| Perceptive Advisors LLC | Investment Adviser | 10.10% | 12,815,113 | 0 | 12,815,113 |
| Joseph Edelman | Individual | 10.10% | 12,815,113 | 0 | 12,815,113 |
| Perceptive Life Sciences Master Fund, Ltd. | CO | 10.00% | 12,649,253 | 0 | 12,649,253 |
Disclosure Items (3)
Common Stock, $0.0001 par value per share
Nautilus Biotechnology, Inc.
2701 Eastlake Avenue East, Seattle, WA, 98102
Item 5(a) of the Schedule 13D is hereby amended and restated as follows: The information set forth in rows 11 and 13 of the cover pages to this Schedule 13D is incorporated by reference. The amounts reported to be beneficially owned by the Reporting Persons include an aggregate of 220,902 shares of Common Stock underlying stock options granted to Mr. Altman (the "Options"). The Master Fund has the right to receive the director compensation provided in respect of Mr. Altman's board service through a partial management fee offset. The percentages set forth in row 13 are based on 126,148,469 outstanding shares of Common Stock as of April 22, 2025, as reported by the Issuer in its Proxy Statement on Schedule 14A filed with the Securities and Exchange Commission on April 29, 2025, and assume the exercise of the Options for an aggregate of 220,902 shares of Common Stock.
The information set forth in rows 7 through 10 of the cover pages to this Schedule 13D is incorporated by reference.